Compare PLTK & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | FTH |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.4M | 835.7M |
| IPO Year | 2020 | 2021 |
| Metric | PLTK | FTH |
|---|---|---|
| Price | $2.05 | $20.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $4.72 | ★ $56.67 |
| AVG Volume (30 Days) | ★ 959.9K | 393.3K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,755,400,000.00 | N/A |
| Revenue This Year | $0.90 | N/A |
| Revenue Next Year | $0.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.08 | N/A |
| 52 Week Low | $2.07 | $17.50 |
| 52 Week High | $4.42 | $42.14 |
| Indicator | PLTK | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.27 | 25.15 |
| Support Level | N/A | N/A |
| Resistance Level | $2.98 | $36.63 |
| Average True Range (ATR) | 0.08 | 2.20 |
| MACD | 0.01 | -0.83 |
| Stochastic Oscillator | 1.67 | 0.85 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.